354 related articles for article (PubMed ID: 16260639)
1. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial.
von Beckerath N; Taubert D; Pogatsa-Murray G; Schömig E; Kastrati A; Schömig A
Circulation; 2005 Nov; 112(19):2946-50. PubMed ID: 16260639
[TBL] [Abstract][Full Text] [Related]
2. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Kastrati A; von Beckerath N; Joost A; Pogatsa-Murray G; Gorchakova O; Schömig A
Circulation; 2004 Oct; 110(14):1916-9. PubMed ID: 15262828
[TBL] [Abstract][Full Text] [Related]
3. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention.
Hochholzer W; Trenk D; Frundi D; Blanke P; Fischer B; Andris K; Bestehorn HP; Büttner HJ; Neumann FJ
Circulation; 2005 May; 111(20):2560-4. PubMed ID: 15809367
[TBL] [Abstract][Full Text] [Related]
4. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.
Gurbel PA; Cummings CC; Bell CR; Alford AB; Meister AF; Serebruany VL;
Am Heart J; 2003 Feb; 145(2):239-47. PubMed ID: 12595840
[TBL] [Abstract][Full Text] [Related]
5. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
[TBL] [Abstract][Full Text] [Related]
6. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
Mitsios JV; Papathanasiou AI; Rodis FI; Elisaf M; Goudevenos JA; Tselepis AD
Circulation; 2004 Mar; 109(11):1335-8. PubMed ID: 15023882
[TBL] [Abstract][Full Text] [Related]
8. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?
Angiolillo DJ; Fernández-Ortiz A; Bernardo E; Barrera Ramírez C; Sabaté M; Fernandez C; Hernández-Antolín R; Escaned J; Alfonso F; Macaya C
J Invasive Cardiol; 2004 Apr; 16(4):169-74. PubMed ID: 15152138
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Storey RF; Husted S; Harrington RA; Heptinstall S; Wilcox RG; Peters G; Wickens M; Emanuelsson H; Gurbel P; Grande P; Cannon CP
J Am Coll Cardiol; 2007 Nov; 50(19):1852-6. PubMed ID: 17980251
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial.
Montalescot G; Sideris G; Meuleman C; Bal-dit-Sollier C; Lellouche N; Steg PG; Slama M; Milleron O; Collet JP; Henry P; Beygui F; Drouet L;
J Am Coll Cardiol; 2006 Sep; 48(5):931-8. PubMed ID: 16949482
[TBL] [Abstract][Full Text] [Related]
11. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Hernández-Antolín R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Macaya C
J Invasive Cardiol; 2004 Jun; 16(6):325-9. PubMed ID: 15156004
[TBL] [Abstract][Full Text] [Related]
12. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
[TBL] [Abstract][Full Text] [Related]
13. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study.
Collet JP; Silvain J; Landivier A; Tanguy ML; Cayla G; Bellemain A; Vignolles N; Gallier S; Beygui F; Pena A; Montalescot G
Circulation; 2008 Sep; 118(12):1225-33. PubMed ID: 18765393
[TBL] [Abstract][Full Text] [Related]
14. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
Brandt JT; Payne CD; Wiviott SD; Weerakkody G; Farid NA; Small DS; Jakubowski JA; Naganuma H; Winters KJ
Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
[TBL] [Abstract][Full Text] [Related]
15. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
[TBL] [Abstract][Full Text] [Related]
16. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study.
L'Allier PL; Ducrocq G; Pranno N; Noble S; Ibrahim R; Grégoire JC; Azzari F; Nozza A; Berry C; Doucet S; Labarthe B; Théroux P; Tardif JC;
J Am Coll Cardiol; 2008 Mar; 51(11):1066-72. PubMed ID: 18342223
[TBL] [Abstract][Full Text] [Related]
17. Effects of statins on platelet inhibition by a high loading dose of clopidogrel.
Müller I; Besta F; Schulz C; Li Z; Massberg S; Gawaz M
Circulation; 2003 Nov; 108(18):2195-7. PubMed ID: 14568892
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
Yong G; Rankin J; Ferguson L; Thom J; French J; Brieger D; Chew DP; Dick R; Eccleston D; Hockings B; Walters D; Whelan A; Eikelboom JW
Am Heart J; 2009 Jan; 157(1):60.e1-9. PubMed ID: 19081397
[TBL] [Abstract][Full Text] [Related]
19. Impact of P-glycoprotein on clopidogrel absorption.
Taubert D; von Beckerath N; Grimberg G; Lazar A; Jung N; Goeser T; Kastrati A; Schömig A; Schömig E
Clin Pharmacol Ther; 2006 Nov; 80(5):486-501. PubMed ID: 17112805
[TBL] [Abstract][Full Text] [Related]
20. Week-long high-maintenance dose clopidogrel regimen achieves better platelet aggregation inhibition than a standard loading dose before percutaneous coronary intervention: results of a double-blind, randomized clinical trial.
Nguyen TA; Lordkipanidzé M; Diodati JG; Palisaitis DA; Schampaert E; Turgeon J; Pharand C
J Interv Cardiol; 2009 Aug; 22(4):368-77. PubMed ID: 19689661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
